PanGen Biotech Inc (222110) - Net Assets
Based on the latest financial reports, PanGen Biotech Inc (222110) has net assets worth ₩30.03 Billion KRW (≈ $20.35 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩32.76 Billion ≈ $22.20 Million USD) and total liabilities (₩2.74 Billion ≈ $1.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PanGen Biotech Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩30.03 Billion |
| % of Total Assets | 91.64% |
| Annual Growth Rate | 8.83% |
| 5-Year Change | 75.28% |
| 10-Year Change | 279.66% |
| Growth Volatility | 138.07 |
PanGen Biotech Inc - Net Assets Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of PanGen Biotech Inc for the complete picture of this company's asset base.
Annual Net Assets for PanGen Biotech Inc (2014–2024)
The table below shows the annual net assets of PanGen Biotech Inc from 2014 to 2024. For live valuation and market cap data, see market value of PanGen Biotech Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩24.91 Billion ≈ $16.88 Million |
+98.22% |
| 2023-12-31 | ₩12.57 Billion ≈ $8.52 Million |
-27.02% |
| 2022-12-31 | ₩17.22 Billion ≈ $11.67 Million |
-18.38% |
| 2021-12-31 | ₩21.10 Billion ≈ $14.30 Million |
+48.46% |
| 2020-12-31 | ₩14.21 Billion ≈ $9.63 Million |
-22.88% |
| 2019-12-31 | ₩18.43 Billion ≈ $12.49 Million |
-31.60% |
| 2018-12-31 | ₩26.94 Billion ≈ $18.26 Million |
-13.95% |
| 2017-12-31 | ₩31.31 Billion ≈ $21.22 Million |
-11.32% |
| 2016-12-31 | ₩35.31 Billion ≈ $23.93 Million |
+438.14% |
| 2015-12-31 | ₩6.56 Billion ≈ $4.45 Million |
-38.62% |
| 2014-12-31 | ₩10.69 Billion ≈ $7.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PanGen Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4404803025000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.45 Billion | 25.89% |
| Other Components | ₩68.41 Billion | 274.65% |
| Total Equity | ₩24.91 Billion | 100.00% |
PanGen Biotech Inc Competitors by Market Cap
The table below lists competitors of PanGen Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
$54.43 Million |
|
Sanica Isi Sanayi A.S.
IS:SNICA
|
$54.43 Million |
|
AC S.A.
WAR:ACG
|
$54.43 Million |
|
Bai Sha Technology Co Ltd
TWO:8401
|
$54.44 Million |
|
Herantis Pharma Oyj
HE:HRTIS
|
$54.41 Million |
|
REDCO PRP GROUP LTD -05
F:8KI
|
$54.40 Million |
|
Finetechnix. Co.Ltd
KQ:106240
|
$54.39 Million |
|
MCE Holdings Bhd
KLSE:7004
|
$54.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PanGen Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,565,977,840 to 24,908,713,350, a change of 12,342,735,510 (98.2%).
- Net income of 943,686,870 contributed positively to equity growth.
- Share repurchases of 9,261,028,660 reduced equity.
- New share issuances of 9,261,028,650 increased equity.
- Other factors increased equity by 11,399,048,650.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩943.69 Million | +3.79% |
| Share Repurchases | ₩9.26 Billion | -37.18% |
| Share Issuances | ₩9.26 Billion | +37.18% |
| Other Changes | ₩11.40 Billion | +45.76% |
| Total Change | ₩- | 98.22% |
Book Value vs Market Value Analysis
This analysis compares PanGen Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.52x to 3.08x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3901.91 | ₩5950.00 | x |
| 2017-12-31 | ₩3256.03 | ₩5950.00 | x |
| 2018-12-31 | ₩2794.17 | ₩5950.00 | x |
| 2019-12-31 | ₩1911.10 | ₩5950.00 | x |
| 2020-12-31 | ₩1473.91 | ₩5950.00 | x |
| 2021-12-31 | ₩1976.95 | ₩5950.00 | x |
| 2022-12-31 | ₩1612.67 | ₩5950.00 | x |
| 2023-12-31 | ₩1176.85 | ₩5950.00 | x |
| 2024-12-31 | ₩1931.18 | ₩5950.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PanGen Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.43%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.23x
- Recent ROE (3.79%) is above the historical average (-24.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -25.82% | -62.35% | 0.20x | 2.05x | ₩-2.94 Billion |
| 2015 | -40.21% | -70.70% | 0.23x | 2.42x | ₩-3.29 Billion |
| 2016 | -14.52% | -350.69% | 0.04x | 1.06x | ₩-8.66 Billion |
| 2017 | -22.41% | -295.67% | 0.07x | 1.14x | ₩-10.15 Billion |
| 2018 | -17.19% | -81.52% | 0.12x | 1.69x | ₩-7.32 Billion |
| 2019 | -48.50% | -310.19% | 0.07x | 2.12x | ₩-10.78 Billion |
| 2020 | -30.65% | -70.36% | 0.17x | 2.55x | ₩-5.78 Billion |
| 2021 | -15.69% | -41.71% | 0.18x | 2.05x | ₩-5.42 Billion |
| 2022 | -26.10% | -69.13% | 0.31x | 1.20x | ₩-6.22 Billion |
| 2023 | -35.72% | -61.36% | 0.35x | 1.65x | ₩-5.75 Billion |
| 2024 | 3.79% | 6.43% | 0.48x | 1.23x | ₩-1.55 Billion |
Industry Comparison
This section compares PanGen Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $368,573,438,392
- Average return on equity (ROE) among peers: 0.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PanGen Biotech Inc (222110) | ₩30.03 Billion | -25.82% | 0.09x | $54.41 Million |
| ORIENTBIO Inc. (002630) | $57.60 Billion | 0.00% | 0.70x | $43.15 Million |
| Green Cross (005250) | $1.51 Trillion | 0.20% | 0.84x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.85 Trillion | 1.30% | 0.98x | $3.74 Million |
| Pharmicell (005690) | $51.52 Billion | 8.44% | 0.23x | $736.42 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $77.34 Million |
About PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more